Conflict of interest: Nothing to report.
Valvular and Structural Heart Diseases
Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: Initial Asia-Pacific experience†
Article first published online: 30 NOV 2011
Copyright © 2011 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 79, Issue 5, pages 794–800, 1 April 2012
How to Cite
Lam, Y.-Y., Yip, G. W.K., Yu, C.-M., Chan, W. W.M., Cheng, B. C.W., Yan, B. P., Clugston, R., Yong, G., Gattorna, T. and Paul, V. (2012), Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: Initial Asia-Pacific experience. Cathet. Cardiovasc. Intervent., 79: 794–800. doi: 10.1002/ccd.23136
- Issue published online: 27 MAR 2012
- Article first published online: 30 NOV 2011
- Accepted manuscript online: 3 MAY 2011 02:14PM EST
- Manuscript Accepted: 19 MAR 2011
- Manuscript Revised: 8 MAR 2011
- Manuscript Received: 3 JAN 2011
- left atrial appendage occlusion;
- Amplatzer cardiac plug;
- atrial fibrillation;
Background: Left atrial appendage (LAA) is the main source of left atrial thrombus that causes stroke in patients with non-valvular atrial fibrillation (NVAF). This study reported the initial safety, feasibility, and 1-yr clinical outcomes following AMPLATZER cardiac plug (ACP) implantation in Asia-Pacific region.Methods: Twenty NVAF patients (16 males, age 68 ± 9 yr) with high risk for developing cardioembolic stroke (CHADS2 score: 2.3 ± 1.3) and contraindications to warfarin received ACP implants from June 2009 to May 2010. Patients received general anesthesia (n = 9) or controlled propofol sedation (n = 11) and the procedures were guided by fluoroscopy and transesophageal echocardiography (TEE). Clinical follow-up was arranged at 1 month and then every 3 months after implantation, whereas, a TEE was scheduled at 1 month upon completion of dual anti-platelet therapy.Results: The LAA was successfully occluded in 19/20 patients (95%) at two Asian centers. One procedure was abandoned because of catheter-related thrombus formation. Other complications included coronary artery air embolism (n = 1) and TEE-attributed esophageal injury (n = 1). The median procedural and fluoroscopic times were 79 (IQR: 59–100) and 18 (IQR 12–27) minutes, respectively. The mean size of implant was 23.6 ± 3.1 mm. The average hospital stay was 1.8 ± 1.1 days. Follow-up TEE showed all the LAA orifices were sealed without device-related thrombus formation. No stroke or death occurred at a mean follow-up of 12.7 ± 3.1 months. Conclusions: Our preliminary data suggested LAA closure with ACP is safe, feasible with encouraging 1-yr clinical outcomes. Further large-scaled trials are needed to confirm the efficacy of this device. © 2011 Wiley Periodicals, Inc.